KMDA Kamada

Kamada Provides Update on 2021 GLASSIA® Supply to Takeda

Kamada Provides Update on 2021 GLASSIA® Supply to Takeda
EN
07/10/2020

Underlying

KMDAKamada

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kamada

 PRESS RELEASE
Free
KMDA KAMADA

Kamada Confirms Continuous Global Business Operations and Products Ava...

Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East REHOVOT, Israel and HOBOKEN, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that, while circumstances in the Middle East are evolving, the Company is continuing the operations and manufacturing at its Israeli facility focusing on business continuity, and ...

June 17, 2025 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada Reports Strong First Quarter 2025 Financial Results with Year O...

Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability Revenues for First Quarter of 2025 of $44.0 Million, Representing a 17% Year-over-Year IncreaseFirst Quarter Adjusted EBITDA of $11.6 Million, Up 54% Year-over-YearStrong Financial Position to Accelerate Growth Through M&A and/or In-licensing Opportunities Announced Expansion of Plasma Collection Operations with Opening of New Site in San Antonio, TexasLaunched Comprehensive Post-Marketing Research Program of CYTOGAM®Reiterating Full Year 2025 Guidance, R...

May 14, 2025 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada to Announce First Quarter 2025 Financial Results on May 14, 202...

Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025 Company to Host Conference Call at 8:30am ET REHOVOT, Israel, and HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter that ended March 31, 2025, prior to the open of the U.S. financial markets on Wednesday, May 14, 2025. ...

May 7, 2025 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada Announces Launch of a Comprehensive Post-Marketing Research Pro...

Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM® Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus (CMV) in Solid Organ TransplantationA Total of 10 Studies will be Conducted in Collaboration with Leading U.S. Physicians, Primarily as Investigator-Initiated Studies (IIS)Results of the Planned Studies are Expected to be Published and/or Presented in Peer Reviewed Industry Journals and Medical Meetings in the Coming Years REHOVOT, Israel, and HOBOKEN, N.J., May 05, 2025 (GLOBE NEWSWIRE) ...

May 5, 2025 1 EN
 PRESS RELEASE
Free
KMDA KAMADA

Kamada Updates on Withholding Tax Procedures on Previously Announced S...

Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders REHOVOT, Israel and HOBOKEN, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the “Ruling”) from the Israel Tax Authority (the “ITA”) with respect to the special cash dividend of $0.20 (approximately NIS 0.72) per share on the Company’...

March 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch